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Objective.T oi n v e s t i g a t et h er e g u l a t o r ye ﬀect of peptidoglycan on the expression of human Toll-like receptors 2 (TLR2) mRNA
and proteins in the human extravillous trophoblast cell line (TEV-1). Methods. TEV-1 cells were incubated with diﬀerent doses
of peptidoglycan. The expression of TLR2 mRNA and protein was detected by reverse transcriptase-polymerase chain reaction
(RT-PCR) and immunocytochemistry SP staining. Results. TLR2 was expressed in TEV-1 cells and localized to both the cytoplasm
and plasma membrane. Compared with the untreated control, TEV-1 cells incubated with 30μg/ml peptidoglycan signiﬁcantly
upregulated the expression of TLR2 mRNA and protein after 12 hours of treatment (P<. 0 1 ) .H o w e v e r ,t h ee x p r e s s i o no f
TLR2 mRNA and protein was decreased but had no signiﬁcant diﬀerence compared with the control (P>. 05) after 24 hours
of treatment. On the other hand, 10μg/ml peptidoglycan did not seem to have regulatory eﬀect on mRNA and protein expression
of TLR2 (P>. 05). Conclusion. Peptidoglycan has a role in regulating the expression of TLR2 mRNA and protein in TEV-1 cells.
It suggests that the trophoblast cells may play important role in the immune response at the fetal-maternal interface and aﬀect the
result of pregnancy by expressing TLR2.
1.Introduction
The maternal-fetal interface represents an immunologically
unique site to protect fetus by maintaining host defense
against a diverse array of possible pathogens. As a conse-
quence, either an ineﬃcient clearance of an infectious
a g e n to ra no v e r a c t i v ei m m u n er e s p o n s em a yh a v ea
signiﬁcant impact on the pregnancy. Clinical studies have
shown a strong association between certain complications
of pregnancy and intrauterine infections [1–3]. It is
reasonable to believe that innate immune responses against
microorganisms at the maternal-fetal interface may have a
signiﬁcant impact on the success of a pregnancy.
The innate immune system responds to infection
through a system of pattern recognition receptors (PRRs)
which recognize conserved sequences known as pathogen-
associated molecular patterns (PAMPs), such as bacterial
lipoproteins, LPS, and peptidoglycan (PGN) [4]. One of the
main families of PRR is toll-like receptors (TLRs). TLRs
are members of a larger family of proteins that includes
the interleukin 1 (IL1) receptor and share a conserved
cytoplasmic domain called the Toll/IL1R (TIR) domain.
TLR signals through the adapter molecule, MyD88, to
activate the NF-κB pathway, which results in an immune
response characterized by the production of cytokines,
antimicrobial products, and the regulation of costimulatory
molecules [5, 6]. Currently there are 13 mammalian Toll-
like receptors homologues that have been identiﬁed—TLR
1–13. In humans, ten functional TLRs (TLRs 1–10) have
been identiﬁed [7, 8]. And studies have demonstrated the2 ISRN Obstetrics and Gynecology
expression of TLR1-10mRNA in human term placenta
[9, 10]. Among the TLRs, TLR2 is believed to recognize
most various infectious pathogens including peptidoglycan
(PGN), which is the main component of the cell wall in
Gram-positive bacteria.
The immunological microenvironment at the maternal-
fetal interface consists of the trophoblast cells, immunolog-
ical cells, and the cytokines [11, 12]. There is growing evi-
dencethattrophoblastcellsareabletorecognizeandrespond
to pathogens through the expression of TLRs. The extrav-
illous trophoblasts are capable of invading the maternal
decidualized endometrium and being part of the fetal cells
which have the direct contact with maternal immunological
system. TEV-1 cell line was originally obtained from primary
cultures of human ﬁrst-trimester placenta which retains all
the established criteria for extravillous trophoblasts [13].
It is proposed that the human extravillous trophoblasts
at the maternal-fetal interface can recognize and respond to
pathogens through expressing TLRs, which may ultimately
aﬀect the outcome of pregnancy. In order to study the role
of TLR2 at maternal-fetal interface, TEV-1 cell was used in
this project as an in vitro model. The regulation of TLR2
by microbial stimulus was assessed by incubating TEV-1
cells with PGN and analysed with reverse transcriptase-
polymerase chain reaction and immunocytochemistry.
2.MaterialsandMethods
2.1. Materials and Reagents. The TLR2 active ligand—a
highly puriﬁed S. aureus peptidoglycan—was used in this
project,anditwasobtainedfromFLUKA(nowSigma,USA).
The mouse monoclonal anti-TLR2 antibody (Santa,USA),
charcoal-stripped FBS (Gibco, USA), SP kit (Wuhan Boster,
China), and TRIzol (Invitrogen, USA) were used in the
experiments. Primers (Shanghai Boya, China), RNAsin,
dNTP, M-MLV, oligo dT Primer, and Taq enzyme (Promega,
USA) were utilized in this project.
2.2. Cell Culture. The human extravillous trophoblast cell
lineTEV-1cellswereculturedinDMEM/F12withoutphenol
red, supplemented with 10% FBS, 12mM L-glutamine, and
100nm of penicillin/streptomycin. The human extravillous
trophoblast cell line TEV-1 cells (1 × 106/ml) were then
incubatedwithnotreatment(medium)asanegativecontrol,
with 10μg/ml PGN for 12 hours or 24 hours, or with
30μg / m lP G Nf o r1 2h o u r so r2 4h o u r s .
2.3. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR) Analysis. Total RNA was isolated from the human
extravillous trophoblast cell line TEV-1 cells by the Trizol
method according to the manufacturer’s instructions. Two
micrograms of total RNA reversely transcribed using dT15
oligonucleotide and Moloney murine leukemia virus reverse
transcriptaseina20μltotalreactionvolume.Twomicroliters
of the reverse transcriptase reaction subjected to PCR
analysis to measure the mRNA levels of TLR2 and β-actin.
PCR ampliﬁcation was performed for TLR2 and β-actin
with Taq polymerase for thirty cycles at 94◦C for thirty
seconds, 54◦C for forty seconds, and 72◦C for one minute.
Primers for TLR2 were 5 -GATGCCTACTGGGTGGAGAA-
3  sense and 5 -CGCAGCTCTCAGATTTACCC-3  antisense
while the size of the product was 393bp. PCR primers for β-
actin were 5 -AGGCCGGTGCTGAGTATGTC-3  sense and
5 -TGCCTGCTTCACCACCTTCT-3  antisense, and the size
of the product was 530bp. The PCR products were separated
by electrophoresis in a 2% agarose gel at 75volts followed
by staining with 1:20 000 dilution of Goldview (a kind of
nucleic acid dye). A 600bp ladder was included with all
experiments to conﬁrm the expected band size. The bands
were then visualized by ultraviolet transillumination and
measured on the basis of the English gel image analysis
system GDS-8000. The intensity of each band was then
normalized to its corresponding β-actin band to semiquan-
titatively compare the values between samples.
2.4. Immunocytochemistry. TEV-1 cells were harvested 12 or
24 hours after stimulation, and they were ﬁxed with ice
acetone for twenty minutes followed by being washed three
times with PBS. The preparations were incubated in a 3%
H2O2 for ten minutes in order to quench endogenous per-
oxidase activity. Paraformaldehyde-ﬁxed trophoblast cells,
previously adhered to glass slides, were blocked with 5%
goat serum in PBS for twenty minutes at room temperature.
Following three washes with PBS, samples were incubated
overnight at 4◦C with the anti-TLR2 monoantibodies while
the PBS was served as negative controls. In addition, speciﬁc
staining after three washes with PBS was also detected by
incubating with a peroxidase-conjugated goat antimouse Ab
(1/100 dilution) for thirty minutes followed by a ﬁve-minute
incubation with diaminobenzidine substrate (Vector Labo-
ratories). Cells and tissue sections were then counterstained
with hematoxylin (Sigma-Aldrich) before dehydration with
ethanol. Slides were visualized by light microscopy, and the
HPIAS-2000 computerized image analysis system was used
to quantitatively determine the expression of TLR2 protein
in terms of staining intensity. Three randomly selected ﬁelds
were obtained from each slide to obtain a mean value (OD
value—a mean value of immunostaining intensity).
2.5. Statistical Analysis. All experiments were repeated three
times, and data were presented with mean ± standard
deviation. Statistical analyses were carried out by using the
SPSS12.0 software, and one-way ANOVA was also used for
statistical purpose. Result with P<. 05 was considered to be
statistically signiﬁcant in this experiment.
3. Results
3.1. The Human Extravillous Trophoblast Cell Line TEV-1
Cells Express TLR2. T h eﬁ r s to b j e c t i v eo ft h i ss t u d yw a st o
determine the expression pattern of TLR2 in the human
extravillous trophoblast cell line TEV-1 cells. As shown in
Figure 2(a), TEV-1 cells showed positive immunoreactivity
for TLR2, and the positive brown granules were mainly
distributed in the cytoplasm and cell membrane. That means
that TLR2 was localized both on the cell surface as well as
intracellularly in TEV-1 cells.ISRN Obstetrics and Gynecology 3
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Figure 1: The expression of TLR2 mRNA in TEV-1 cells.
Table 1: The expression of TLR2 in TEV-1 cells (x ±s).
Groups TLR2 mRNA TLR2 protein
12 hours
Control 0.212 ±0.028 0.135 ±0.016
PGN 10μg/ml ×12 hours 0.261 ±0.059 0.135 ±0.021
PGN 30μg/ml ×12 hours 0.415 ±0.063
∗ 0.200 ±0.025
∗
24 hours
Control 0.200 ±0.016 0.132 ±0.016
PGN 10μg/ml ×24 hours 0.198 ±0.024 0.134 ±0.019
PGN 30μg/ml ×24 hours 0.145 ±0.014 0.122 ±0.014
∗P<. 01 as compared with the other ﬁve groups.
3.2. TLR2 mRNA and Protein Expression after PGN Stimula-
tion. As shown in Figures 1 and 2,a sw e l la sTable 1,T E V - 1
cellswerestimulatedwithdiﬀerentconcentrationsofPGNor
incubated with medium alone for 12- and 24-hour period.
Compared with the control, TEV-1 cells incubated with
30μg/ml peptidogly can be shown to signiﬁcantly upregulate
the expression of TLR2 mRNA and protein after 12 hours of
treatment (P<. 01). However, when it was allowed to last to
24 hours, the expression of TLR2 mRNA and protein were
decreased (as compared with the 12-hour group) but had no
signiﬁcant diﬀerence compared with the control (P>. 05).
On the other hand, 10μg/ml peptidoglycan did not aﬀect the
expression of TLR2 mRNA and protein after either 12 hours
or 24 hours (P>. 05) of treatment.
4. Discussion
Intrauterine infection aﬀects the placental development and
function. It can subsequently leads to complications of
pregnancy such as preterm labor and delivery, fetal growth
restriction (FGR) and preeclampsia [1–3]. However, the
precise adverse reaction of intrauterine infection is yet to
be deﬁned. TLRs are the key components of the innate
immune system which recognize conserved sequences on the
surface of pathogens and trigger the eﬀector cell functions.
Researchers found that TLR2 expression was signiﬁcantly
higher in patients with chorioamnionitis than in those
without this condition [14]. The TLR2 expression was found
tobepolarizedtothebasalsurfaceofamnioticepithelialcells
in patients without chorioamnionitis, but this distribution
was lost in the presence of inﬂammation. It is suggested
that TLR2 may play an important role in immunological
respondse at maternal-fetal interface [14]. In our study,
immuno-cytochemical staining of TEV-1 cells revealed that
the TLR2 was highly expressed intracellularly as well as being
expressed on the cell surface. Such cytoplasmic expression
may provide rapid mobilization of additional receptors
to the cell surface following initial bacterial recognition.
Alternatively, cytoplasmic expression may serve to facilitate
intracellular recognition and responses. The cytoplasmic
expression was also found in human dendritic cells [15].
A study in the human placenta cultures demonstrated
that stimulation with zymosan and LPS for 2–6 hours readily
induced interleukin- (IL- ) 6 and IL-8 cytokine production,
whereasTLR2mRNAandproteinexpressionremainedatthe
same high level as in unstimulated explants [16]. However,4 ISRN Obstetrics and Gynecology
(a)
(b)
(c)
(d)
(e)
(f)
(a) 12h control
(b) PGN 10μg/mL × 12h
(c) PGN 30μg/mL × 12h
(d) 24h control
(e) PGN 10μg/mL × 24h
(f) PGN 30μg/mL × 24h
Figure 2: The expression of TLR2 protein in TEV-1 cells (immunocytochemistry SP ×200).
in our experiments we found that, when comparing with
the untreated control, TEV-1 cells incubated with 30μg/ml
PGN could signiﬁcantly up-regulate the expression of TLR2
mRNA and protein after 12 hours of treatment (P<
.05). When the incubation period lasted to 24 hours, the
expression of TLR2 mRNA and protein was decreased as
compared with the 12 hours group, even though there was
no statistically signiﬁcance while comparing with the control
(P>. 05). It is proposed that the diﬀerence of the results
obtained in our experiments and other reported studies may
be related to diﬀerent kinds and doses of stimulants used,
diﬀerent cells and tissue applied, and also the duration of
stimulation applied.
In our experiment, two time points 0–12 hours–24 hours
and two dose points 0–10μg/ml–30μg/ml were set for deter-
mination of outcomes. In the 12 hours of treatment group,
10μg/ml PGN did not aﬀect the expression of TLR2 whereas
30μg/ml PGN increased the expression. This suggested that
there may be a dose-dependent manner, which may conduce
to recognize and respond to more pathogens. In the 24
hours treatment group, 10μg/ml PGN still did not aﬀect the
expression of TLR2, but 30μg/ml decreased the expression.
We believed that when stimulate time is prolonged, the dose-
dependentmannermaydisappearduetothehighdosePGN-
induced cells apoptosis. There are reports on PGN to induce
trophoblast apoptosis through TLR2 [17]. Holmlund et al.
(2002) [16] incubated the ﬁrst trimester trophoblast cells
(H8) with PGN (80μg/ml), following 48 hours of treatment.
It resulted in a 61.72% increase in the number of apoptotic
trophoblast cells compared with the untreated control. It was
suggested not related to simple dose- and time-dependent
manner but rather a complicated regulatory eﬀect. Thus theISRN Obstetrics and Gynecology 5
extravillous trophoblast cells may play important roles in the
immune response at the fetal-maternal interface.
5. Conclusion
T h em R N Aa n dp r o t e i no fT L R 2a r es h o w nt oe x p r e s s
in the human extravillous trophoblast cells TEV-1, and
peptidoglycan may stimulate the expression of TLR2 in TEV-
1 cells. It is indicated that the extravillous trophoblast cells
may play important roles in the immune response at the
fetal-maternal interface and aﬀect the pregnancy outcome
by expressing TLR2. Such altered trophoblast cell responses
may contribute to the pathogenesis of certain pregnancy
complications.
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